F10 and deep vein thrombosis: In a subgroup analysis that examined the results of the Chinese patients included in the EINSTEIN-DVT (Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients with Acute Symptomatic Deep Vein Thrombosis) and EINSTEIN-PE (Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients with Acute Symptomatic Pulmonary Embolism) trials, 9.2% (20/218) of patients receiving VKA therapy experienced a major or CRNM bleeding event [111].